+714-246-4249

Examiner: Brian S. Kwon

Art Unit: 1614

Conf. No.: 7685

T-560 P.01/12 F-761

17501CON(AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

MAR U 2 2006

In re Application of: Chang et. al.

Customer No.: 051957 Serial No:10/685,941

Filed: October 14, 2003

For: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR

TOPICAL OPHTHALMIC USE

INFORMATION DISCLOSURE STATEMENT

Attn: Information Disclosure Statement

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22310-1450

Dear Sir:

Applicants herewith submit form PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR §§ 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicants make no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicants make no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

Please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted.

Date:

Brent A. Johnson Reg. No. 51,851 ALLERGAN, INC. 2525 Dupont Drive Irvine, CA 92612

Tel: 714-246-4348/Fax: 714-246-4249

CERTIFICATE OF FAX TRANSMISSION

I HEREBY, CERTIFY THAT THIS CORRESPONDENCE IS BEING TRANSMITTED TO THE CENTRAL FAX NUMBER 571-273-8300.

2006 (Date) Name of person making deposit: Bonnie Eerquson

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17501 CON (AP)	SERIAL NO.: 10/685,941
APPLICANT:	CHIN-MING CHANG, et al	TITLE: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE:	October 14, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
					·	

FOREIGN PATENT DOCUMENTS

	 DOCUMENT NO.	DATÉ	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
-						

OTHER REFERENCES

(including Author, Title, Date, Pertinent Pages, etc.)

1		
1	I DA	Goni, "12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the
- 1		
- 1		individual components in patients with glaucoma and ocular hypertension", European Journal of Ophthalmology,
- 1	i	Val 15 No 5 2005 pp. 581-590
		I VAL 15 NA 5 7005 00 00 00 0

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

+714-246-4249

T-560 P.01/12 F-762

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chang et. al.

Customer No.: 051957 Serial No:10/685,941

Filed: October 14, 2003

For: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR

TOPICAL OPHTHALMIC USE

Examiner: Brian S. Kwon

Art Unit: 1614

Conf. No.: 7685

RECEIVED CENTRAL FAX CENTER

MAR U 2 2006

INFORMATION DISCLOSURE STATEMENT

Attn: Information Disclosure Statement

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22310-1450

Dear Sir:

Applicants herewith submit form PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR §§ 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicants make no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicants make no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

Please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted.

Date:

Reg. No. 51,851 ALLERGAN, INC. 2525 Dupont Drive

Irvine, CA 92612

Tel: 714-246-4348/Fax: 714-246-4249

CERTIFICATE OF FAX TRANSMISSION

HEREBY, CERTIFY THAT THIS CORRESPONDENCE IS BEING TRANSMITTED TO THE CENTRAL FAX NUMBER 571-273-8300,

2006 (Date) Name of person making deposit: Bonnie Ferguson

Signature

+714-246-4249

T-560 P.02/12 F-762

Sheet _2_ of 2_

PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17501 CON (AP)	SERIAL NO.: 10/685,941
APPLICANT:	CHIN-MING CHANG, et al.	TITLE: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE:	October 14, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	 DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
						(и арриодыіс)

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

DA	Goni, "12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the
	individual components in patients with glaucoma and ocular hypertension", European Journal of Ophthalmology,
 	Vol. 15, No. 5, 2005, pp. 581-590

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.